Some statistical considerations in the clinical development of cancer immunotherapies.

  • Bo Huang
  • Published 2018 in Pharmaceutical statistics


Immuno-oncology has emerged as an exciting new approach to cancer treatment. Common immunotherapy approaches include cancer vaccine, effector cell therapy, and T-cell-stimulating antibody. Checkpoint inhibitors such as cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/L1 antagonists have shown promising results in multiple indications in… (More)
DOI: 10.1002/pst.1835


3 Figures and Tables